AUA Practice Management & Coding Program: Friday Session (2023)
Availability
No future session
Expires on Jul 14, 2026
Cost
$0.00
Credit Offered
6.25 AMA PRA Category 1 Credit Credits
6.25 Participation Credits

Attend Live Virtual on Friday, July 14, 2023 ONLY!

Designed specifically with the practice administrator and coder in mind, this 2-day, virtual program addresses the hot topics facing today's urology practices and offers practical advice on how to survive and thrive in the current environment. APPROVED FOR 13 CEU's!

FEATURING COURSE CO-DIRECTORS

  • Angela Gilfillan, CMPE, CASC
  • Edna R. Maldonado, CPC, ACS-UR, ICD-10-CM AHIMA Trainer

CODING & REIMBURSEMENT HIGHLIGHTS

  • Evaluation & Management (E/M) Services Update
  • 2023 CPT Code Changes: Need to Know Updates and Clarifications
  • Billing in the Ambulatory Surgery Center (ACS)
  • Correct Use of Modifiers
  • Strategies for Denials; Maximizing your Revenue Stream
  • Public Health Emergency (PHE) Updates: Urology After the PHE
  • 2023 Medicare Updates: Comment Period Hot Topics

 


Registration Fees

LIVE VIRTUAL

 

Live Virtual: Both Days

Live Virtual: Thursday Only

Live Virtual: Friday Only

Member/Practice Managers' Network (PMN) Subscriber

$875

$545

$545

Non-member

$1,095

$685

$685

  • Practice Administrators
  • Coders
  • Physicians involved in managing a urology practice
  • Other Office Staff

At the conclusion of this course, participants will be able to:

  1. Determine coding for the appropriate level of evaluation and management.
  2. Interpret and apply billing and coding for proper reimbursement.
  3. Identify and apply best practices in billing processes within an ambulatory surgery center to optimize revenue capture and ensure compliance.
  4. Identify the practice implications created by the expiration of the Public Health Emergency (PHE).
  5. Accurately identify and apply appropriate modifiers in urology coding scenarios, understand the impact of modifiers on reimbursement, and effectively navigate modifier-related challenges to optimize coding accuracy and revenue capture within their medical practice.
  6. List the changes to Medicare Program for 2023.
  7. Identify common causes of claim denials, implement proactive strategies to minimize denials, and develop effective techniques to maximize revenue by effectively appealing and resolving denied claims within their urology practice.
  8. Code complex urological issues and multiple procedures.

EDUCATION COUNCIL DISCLOSURES

Education Council Disclosures.pdf

COI REVIEW WORK GROUP DISCLOSURES

COI Review Work Group Disclosures.pdf

Course Co-director(s)

Angela Gilfillan has no relevant financial relationships to disclose at this time.
 
Edna Maldonado has no relevant financial relationships to disclose at this time.

Faculty(s)

Stephanie Allard has no relevant financial relationships to disclose at this time.

Holly Ezell has no relevant financial relationships to disclose at this time.
 
Jeffrey Gorke, MBA has no relevant financial relationships to disclose at this time.

Richard Kes has no relevant financial relationships to disclose at this time.
 
James Kovavik, PA-Chas no relevant financial relationships to disclose at this time.
 
Mark Painter, CEO has a financial relationship (Leadership Position (General Urology)) with Relative Value Studies, Inc.;
 
financial relationship (Leadership Position (General Urology)) with Physician Reimbursement Systems;
 
financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Contura;
 
financial relationship (Consultant or Advisor (Specialty Not Specified)) with iUflow;
 
financial relationship (Leadership Position (General Urology)) with PRS, LLC;
 
financial relationship (Consultant or Advisor (General Urology)) with Boston Scientific;
 
financial relationship (Consultant or Advisor (General Urology)) with Photocure;
 
financial relationship (Leadership Position (General Urology)) with PRS Managed Services, LLC;
 
financial relationship (Consultant or Advisor (General Urology)) with SRS Medical, Inc.;
 
financial relationship (Consultant or Advisor (General Urology)) with ODX;
 
financial relationship (Consultant or Advisor (General Urology)) with Soundable Health;
 
financial relationship (Consultant or Advisor (General Urology)) with Sonacare;
 
financial relationship (Consultant or Advisor (General Urology)) with Swan Valley Medical;
 
financial relationship (Consultant or Advisor (General Urology)) with Novuhealth;
 
financial relationship (Consultant or Advisor (General Urology)) with HIFU Prostate Services, Inc;
 
financial relationship (Consultant or Advisor (General Urology)) with Medeon;
 
financial relationship (Consultant or Advisor (General Urology)) with Vensica;
 
financial relationship (Consultant or Advisor (Oncology)) with Fergene;
 
financial relationship (Consultant or Advisor (General Urology)) with Medtronic;
 
financial relationship (Consultant or Advisor (General Urology)) with StreamDx;
 
financial relationship (Consultant or Advisor (Oncology)) with UroGen;
 
financial relationship (Consultant or Advisor (Specialty Not Specified)) with Applaud Medical;
 
financial relationship (Leadership Position (General Urology)) with PRS Consulting.
 
Jonathan N. Rubenstein, MD has no relevant financial relationships to disclose at this time.
 
Daniel Schonwald, BA has a financial relationship (Other (General Urology)) with LUGPA.
 
Sean Weiss, CPC has no relevant financial relationships to disclose at this time.

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

AUA ACCREDITATION INFORMATION

ACCREDITATION:

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION:

The American Urological Association designates this live activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS:

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 CreditsTM.

EVIDENCE BASED CONTENT:

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY:

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.